Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

The ethics of being on a pharmaceutical advisory board

David B. Nash, MD, MBA
Meds
August 27, 2011
180 Shares
Share
Tweet
Share

While diligently perusing a stack of unread journals, a piece in the July 25, 2011 issue of Modern Healthcare caught my attention.

Titled “What’s the Agenda?” this special report deftly navigated the murky waters of “physician participation on advisory boards” and managed to present an accurate appraisal of the issues.

Here is a brief recap.

Back in the days before “medical ethics” issues were commonplace, pharmaceutical and medical device manufacturers were accustomed to inviting physicians to a nice hotel or resort ostensibly to “answer questions that would help improve cutting edge therapies.”

Often this meant asking physicians to give their impressions of promotional materials in terms of their likely influence on other physicians.

In essence, the lines were a little fuzzy. Was the advisory board really about marketing? If so, who was the intended audience — the physicians themselves or the ultimate consumers?

For pharmaceutical and medical device manufacturers, the case for physician advisory boards is clear cut and very practical.

Obviously, making physicians aware of a particular product in the course of board discussions may steer them toward using it in their practice.

However, consulting arrangements with physicians are considered to be essential for developing and, more importantly, improving upon technologies.

True, there may be no way to completely avoid influencing decisions. The question is one of how a physician advisory board can remain objective and how to minimize the risk of bias – for example, a physician participant being predisposed to use a product or device regardless of what might be in the best interest of the patient.

It is a delicate balance, but the key is to develop agendas and design consulting and advisory agreements so as to ensure that the physician’s focus is always on the best interest of each patient.

There has been a lot of conversation and a great deal of background noise on this topic for years. So, I asked myself why Modern HealthCare would decide to devote two full pages and a couple of charts to this topic at this particular time.

Whatever the reason, the timing couldn’t be better!

In the wake of intense scrutiny – and equally intense criticism – we are seeing a paradigm change around interactivity among physicians and industry.

First and foremost is evidence of the industry’s commitment to ethical practices. The Pharmaceutical Research and Manufacturers Association (PhRMA) developed a voluntary “Code on Interactions with Healthcare Professionals” that includes strict limits on how drug makers reimburse physicians for advice. The code is now endorsed by 55 biopharmaceutical companies.

The rationale is that it is reasonable to pay physicians to consult if the advisory board’s mission is narrowly defined to address a specific problem and the fees are “at fair market value for the services provided.” Posh resorts and lavish entertainment are now taboo.

Second is the fine work of the Accreditation Council for Continuing Medical Education (ACCME) in issuing guidelines and updating policies to ensure that CME developed with financial grant support from PhRMA is certified and delivered without bias.

Finally, there is public sector oversight. Since 2003, the Office of the Inspector General of the Department of Health and Human Services has required pharmaceutical organizations to separate their sales/promotional activities from educational activities.

And, on the horizon is the Physician Payment Sunshine Provisions, included in healthcare reform act, that requires drug and device manufacturers to track payments to physicians (over $10) beginning in 2012. In 2013, these disclosures will be posted on a publicly searchable Web site.

After more than a decade of working closely with multiple stakeholders including pharmaceutical and medical device companies to convene physician advisory boards here at Jefferson School of Population Health, my personal rules are pretty much set in stone … and they work.

  1. Define a goal (or goals) and set an agenda centered on a policy related discussion that is unrelated to a specific product.
  2. Recruit appropriate physician advisory board participants with transparency.
  3. Pay physician participants a reasonable fee to accomplish the specified goal or goals.

Back in 2003, I wrote an editorial for the Health Policy Newsletter entitled, “Seeking Middle Ground.” At the time, there was a slew of adverse publicity with regard to perceived conflict of interest with regard to advisory boards.

Controversy will remain and the debate is likely to continue but, for me, the wisest place to chart a course is somewhere in the middle ground.

David B. Nash is Founding Dean of the Jefferson School of Population Health at Thomas Jefferson University and blogs at Nash on Health Policy.

Originally published in MedPage Today. Visit MedPageToday.com for more health policy news.

Prev

The trouble with Dr. Google

August 27, 2011 Kevin 49
…
Next

Why I love community health fairs

August 27, 2011 Kevin 0
…

Tagged as: Medications

Post navigation

< Previous Post
The trouble with Dr. Google
Next Post >
Why I love community health fairs

More by David B. Nash, MD, MBA

  • Does the House of God stand the test of time?

    David B. Nash, MD, MBA
  • a desk with keyboard and ipad with the kevinmd logo

    Nonprofit hospitals: The potential for conflict of interest is huge

    David B. Nash, MD, MBA
  • a desk with keyboard and ipad with the kevinmd logo

    Quality measures benefit from quality improvement

    David B. Nash, MD, MBA

More in Meds

  • The deadly consequences of a shortage: The Pluvicto crisis leaves metastatic prostate cancer patients in limbo

    Matt Drewes
  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • The cannabis education gap: Why patients are left in the dark

    Timothy Byars
  • Are doctors ready to discuss psychedelic therapies with patients?

    Thaís Salles Araujo, MD
  • The rise and dark side of fungi: Exploring health benefits and pathogenic threats

    Sandra Vamos, EdD and Deanna Lernihan, MPH
  • Advocacy and collaboration lead to major patient safety benefits on sterile pharmaceutical compounding: a review of USP’s revisions to Chapter <797>

    Elizabeth Rebello, MD
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
  • Past 6 Months

    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Unveiling the global pandemic threat: insights into risk factors and urgent measures for prevention

      Ton La, Jr., MD, JD | Policy
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Empowering Black nurses for lasting change [PODCAST]

      The Podcast by KevinMD | Podcast
    • Master time management with 7 productivity strategies for optimal results

      Farzana Hoque, MD | Physician
    • Proposed USPSTF guideline update: Advocating for earlier breast cancer screening at age 40

      Hoag Memorial Hospital Presbyterian | Conditions
    • The rising threat of lung cancer in Asian American female nonsmokers

      Alice S. Y. Lee, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer
  • What Was Tied to Lower Long COVID Risk?
  • Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
  • Two-Drug Combo Wins for Refractory Gout
  • First-in-Class Sjogren's Drug Passes Mid-Stage Test

Meeting Coverage

  • Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer
  • Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
  • Two-Drug Combo Wins for Refractory Gout
  • First-in-Class Sjogren's Drug Passes Mid-Stage Test
  • Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
  • Past 6 Months

    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Unveiling the global pandemic threat: insights into risk factors and urgent measures for prevention

      Ton La, Jr., MD, JD | Policy
    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Empowering Black nurses for lasting change [PODCAST]

      The Podcast by KevinMD | Podcast
    • Master time management with 7 productivity strategies for optimal results

      Farzana Hoque, MD | Physician
    • Proposed USPSTF guideline update: Advocating for earlier breast cancer screening at age 40

      Hoag Memorial Hospital Presbyterian | Conditions
    • The rising threat of lung cancer in Asian American female nonsmokers

      Alice S. Y. Lee, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

The ethics of being on a pharmaceutical advisory board
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...